FDA allows automatic ‘generic’ swap for brand-name insulin
By The Associated Press - | Jul 29, 2021
This July 2021 image provided by Viatris shows Semglee insulin. On Wednesday, July 28, 2021, U.S. regulators took action that will make it easier to get a cheaper and similar version of a brand-name insulin at the drugstore. The Food and Drug Administration agreed that Viatris Inc.’s Semglee was interchangeable with widely use Lantus, a fast-acting insulin. (Viatris via AP)
SIGN UP TO CONTINUE
Print Subscriber? Sign Up for Full Access!
Please sign up for as low as 36 cents per day to continue viewing our website.
Digital subscribers receive
Unlimited access to all stories from nashuatelegraph.com on your computer, tablet or smart phone.
Access nashuatelegraph.com, view our digital edition or use our Full Access apps.
Get more information at nashuatelegraph.com/fullaccess